摘要
硼中子俘获治疗(boron neutron capture therapy, BNCT)是二元靶向放射治疗方法,中子并不直接提供肿瘤治疗剂量,而是利用肿瘤靶向10B携带剂将10B(n, α)7Li俘获反应产生的剂量沉积于肿瘤细胞。因此了解血液、肿瘤组织和正常组织中10B携带剂的生物分布对于BNCT临床治疗是必不可少的。目前国际上BNCT临床主要使用4-硼-L-苯丙氨酸(4-borono-L-phenylalanine, BPA)为硼携带剂。本文简要总结了BPA的结构、理化特性、细胞摄取机制以及人体生物分布等数据,目的是支持和促进基于BPA的BNCT临床试验准备。
Boron neutron capture therapy(BNCT)is a binary targeted radiation therapy in which neutron does not directly provide tumor dose.The dose produced by the 10 B(n,α)7Li capture reaction will be deposited in tumor cells by using targeted 10 B agents.Therefore,understanding the biological distribution of 10 B agents in the blood,tumor and normal tissue is essential for BNCT.4-borono-L-phenylalanine(BPA)is the mainly used 10 B agent in BNCT clinical trials worldwide.In order to support and facilitate the preparation of BPA-based BNCT clinical trials,information on the structure,physicochemical properties,cellular uptake mechanisms and human biological distribution of BPA are summarized in this paper.
作者
祝夏阳
刘凯
邵玉军
金从军
赵春元
崇奕峥
郭志滨
孙琪
刘志博
刘彤
张紫竹
ZHU Xia-yang;LIU Kai;SHAO Yu-jun;JIN Cong-jun;ZHAO Chun-yuan;CHONG Yi-zheng;GUO Zhi-bin;SUN Qi;LIU Zhi-bo;LIU Tong;ZHANG Zi-zhu(Beijing Nuclear Industry Hospital,Beijing 102413,China;China Zhongyuan Engineering Corporation,Beijing 100083,China;College of Chemistry and Molecular Engineering,Peking University,Beijing 100871,China;Beijing Capture Technology Limited Co.,Beijing 102413,China)
出处
《核化学与放射化学》
CAS
CSCD
北大核心
2023年第6期477-486,I0002,共11页
Journal of Nuclear and Radiochemistry
基金
中核集团基础研究项目(CNNC-JCYJ-202214)
中国宝原科研基金(ZHYL-BHY-2021001)
中核医疗核医科技创新项目(ZHYL-ZD-2021003)。
